As of 2026-05-26, the Intrinsic Value of Shenzhen Bioeasy Biotechnology Co Ltd (300942.SZ) is 1.36 CNY. This 300942.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7.07 CNY, the upside of Shenzhen Bioeasy Biotechnology Co Ltd is -80.80%.
The range of the Intrinsic Value is 0.82 - 3.39 CNY
Based on its market price of 7.07 CNY and our intrinsic valuation, Shenzhen Bioeasy Biotechnology Co Ltd (300942.SZ) is overvalued by 80.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.82 - 3.39 | 1.36 | -80.8% |
| DCF (Growth 10y) | 1.27 - 4.99 | 2.06 | -70.9% |
| DCF (EBITDA 5y) | 9.23 - 13.27 | 11.13 | 57.4% |
| DCF (EBITDA 10y) | 9.15 - 15.72 | 12.04 | 70.4% |
| Fair Value | 0.08 - 0.08 | 0.08 | -98.81% |
| P/E | 0.69 - 1.20 | 0.88 | -87.6% |
| EV/EBITDA | 1.60 - 5.08 | 3.26 | -53.9% |
| EPV | (2.81) - (4.27) | (3.54) | -150.1% |
| DDM - Stable | 0.12 - 0.57 | 0.35 | -95.1% |
| DDM - Multi | 0.93 - 2.72 | 1.33 | -81.2% |
| Market Cap (mil) | 2,863.84 |
| Beta | 1.75 |
| Outstanding shares (mil) | 405.07 |
| Enterprise Value (mil) | 2,975.41 |
| Market risk premium | 6.13% |
| Cost of Equity | 10.08% |
| Cost of Debt | 5.00% |
| WACC | 9.29% |